11 – 20 of 30
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
(
- Contribution to journal › Article
-
Mark
A Panel of Kallikrein Marker Predicts Prostate Cancer in a Large, Population-Based Cohort Followed for 15 Years without Screening
(
- Contribution to journal › Article
-
Mark
Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively
(
- Contribution to journal › Article
- 2010
-
Mark
Finasteride to prevent prostate cancer : Should all men or only a high-risk subgroup be treated?
(
- Contribution to journal › Article
-
Mark
Empirical Estimates of the Lead Time Distribution for Prostate Cancer Based on Two Independent Representative Cohorts of Men Not Subject to Prostate-Specific Antigen Screening.
2010) In Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology May 4. p.1201-1207(
- Contribution to journal › Article
-
Mark
A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up : An independent validation study from the European Randomized Study of Prostate Cancer screening, France
(
- Contribution to journal › Article
-
Mark
Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication.
(
- Contribution to journal › Article
-
Mark
A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam
(
- Contribution to journal › Article
-
Mark
Prostate Specific Antigen Velocity Does Not Aid Prostate Cancer Detection in Men With Prior Negative Biopsy
(
- Contribution to journal › Article
-
Mark
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
(
- Contribution to journal › Article